DGI:ZNS-Infektionen/Tuberkulose Meningitis/Diagnostik - Revision history

imported>Kristina.jozic at 09:04, 17 March 2026

2026-03-17T09:04:55Z

← Older revision		Revision as of 09:04, 17 March 2026
Line 77:		Line 77:
	Goldstandard: Kultur auf Tbc (sensitiver als Mikroskopie, ist in bis zu 50-70% positiv). Dauer der Kultur bis 8 (-12) Wochen <span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref name=":0">Schaberg T, Bauer T, Brinkmann F, et al. [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017;71(6):325-397. doi:10.1055/s-0043-105954</ref><ref>Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581-598. doi:10.1038/nrneurol.2017.120</ref><ref>Ducomble T, Tolksdorf K, Karagiannis I, et al. The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill. 2013;18(12):20436.</ref><ref>National Collaborating Centre for Chronic Conditions (UK), Centre for Clinical Practice at NICE (UK). Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. National Institute for Health and Clinical Excellence (UK); 2011. Accessed August 9, 2021. <nowiki>http://www.ncbi.nlm.nih.gov/books/NBK97852/</nowiki></ref><ref>Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-187. doi:10.1016/j.jinf.2009.06.011</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Chin JH. Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract. 2014;4(3):199-205. doi:10.1212/CPJ.0000000000000023</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-812. doi:10.1016/S1473-3099(10)70138-9</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span>.		Goldstandard: Kultur auf Tbc (sensitiver als Mikroskopie, ist in bis zu 50-70% positiv). Dauer der Kultur bis 8 (-12) Wochen <span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref name=":0">Schaberg T, Bauer T, Brinkmann F, et al. [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017;71(6):325-397. doi:10.1055/s-0043-105954</ref><ref>Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581-598. doi:10.1038/nrneurol.2017.120</ref><ref>Ducomble T, Tolksdorf K, Karagiannis I, et al. The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill. 2013;18(12):20436.</ref><ref>National Collaborating Centre for Chronic Conditions (UK), Centre for Clinical Practice at NICE (UK). Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. National Institute for Health and Clinical Excellence (UK); 2011. Accessed August 9, 2021. <nowiki>http://www.ncbi.nlm.nih.gov/books/NBK97852/</nowiki></ref><ref>Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-187. doi:10.1016/j.jinf.2009.06.011</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Chin JH. Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract. 2014;4(3):199-205. doi:10.1212/CPJ.0000000000000023</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-812. doi:10.1016/S1473-3099(10)70138-9</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span>.

	~~Xpert MTB/Rif, PCR zur Bestimmung von Tbc~~ sowie ~~Rifampicin-Resistenz, welches ein Hinweis für~~ eine ~~MDR~~-~~Tbc ist~~. Die Verlässlichkeit eines resistenten Ergebnisses (positiv prädiktiver Wert) ist abhängig von der Häufigkeit der Resistenz in der untersuchten Bevölkerung. Liegt die MDR-Rate, wie in Deutschland, unter 5%, sinkt der positiv prädiktive Wert auf unter 70% <ref name=":0" />		Es sollte eine kulturelle Resistenzbestimmung für die Medikamente der Standardtherapie erfolgen sowie zusätzlich eine molekularbiologische Analyse hinsichtlich der Genabschnitte mit einer Isoniazid- und Rifampicinresistenz. Die Verlässlichkeit eines resistenten Ergebnisses (positiv prädiktiver Wert) ist abhängig von der Häufigkeit der Resistenz in der untersuchten Bevölkerung. Liegt die MDR-Rate, wie in Deutschland, unter 5%, sinkt der positiv prädiktive Wert auf unter 70% <ref name=":0" />

	===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===		===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===

imported>Fuhrmanns at 19:52, 9 August 2021

2021-08-09T19:52:47Z

← Older revision		Revision as of 19:52, 9 August 2021
Line 85:		Line 85:
	*Parasiten: ''Echinokokkus'' spp., Toxoplasma		*Parasiten: ''Echinokokkus'' spp., Toxoplasma
	*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)		*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)
	~~<references />~~

imported>Fuhrmanns at 19:49, 9 August 2021

2021-08-09T19:49:25Z

← Older revision		Revision as of 19:49, 9 August 2021
Line 30:		Line 30:
	\|-		\|-
	!Aspekt		!Aspekt
	\|~~klar~~		\|Klar
	\|~~klar~~		\|Klar
	\|~~trüb~~		\|Trüb
	\|~~klar~~-trüb		\|Klar-trüb
	\|-		\|-
	!Druck (cm H2O)		!Druck (cm H2O)
Line 85:		Line 85:
	*Parasiten: ''Echinokokkus'' spp., Toxoplasma		*Parasiten: ''Echinokokkus'' spp., Toxoplasma
	*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)		*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)
			<references />

imported>Fuhrmanns at 19:48, 9 August 2021

2021-08-09T19:48:08Z

← Older revision		Revision as of 19:48, 9 August 2021
Line 1:		Line 1:
	~~==<span class="mw-headline" id="Diagnose" style="box-sizing: inherit;">Diagnose</span>==~~

	====Anamnese====		====Anamnese====

imported>Bestem at 18:47, 9 August 2021

2021-08-09T18:47:30Z

← Older revision		Revision as of 18:47, 9 August 2021
Line 77:		Line 77:


	Goldstandard: Kultur auf Tbc (sensitiver als Mikroskopie, ist in bis zu 50-70% positiv). Dauer der Kultur bis 8 (-12) Wochen <span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref~~><span style~~="~~font-size:12.0pt;line-height:107%;~~		Goldstandard: Kultur auf Tbc (sensitiver als Mikroskopie, ist in bis zu 50-70% positiv). Dauer der Kultur bis 8 (-12) Wochen <span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref name=":0">Schaberg T, Bauer T, Brinkmann F, et al. [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017;71(6):325-397. doi:10.1055/s-0043-105954</ref><ref>Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581-598. doi:10.1038/nrneurol.2017.120</ref><ref>Ducomble T, Tolksdorf K, Karagiannis I, et al. The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill. 2013;18(12):20436.</ref><ref>National Collaborating Centre for Chronic Conditions (UK), Centre for Clinical Practice at NICE (UK). Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. National Institute for Health and Clinical Excellence (UK); 2011. Accessed August 9, 2021. <nowiki>http://www.ncbi.nlm.nih.gov/books/NBK97852/</nowiki></ref><ref>Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-187. doi:10.1016/j.jinf.2009.06.011</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Chin JH. Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract. 2014;4(3):199-205. doi:10.1212/CPJ.0000000000000023</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-812. doi:10.1016/S1473-3099(10)70138-9</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span>.
	~~font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";~~
	~~mso-ansi-language~~:~~EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA~~">8. Schaberg T, et al., Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP). Pneumologie 2017; ~~'''~~71~~'''~~(6): 325-397</~~span>~~</ref><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman"~~,~~serif;~~
	~~mso-fareast-font-family:"Times New Roman"">9. Wilkinson RJ~~, et al., Tuberculous meningitis''.'' Nat Rev Neurol, 2017; ~~'''~~13~~'''~~(10): 581-598</~~span>~~</ref><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman"~~,~~serif;~~
	~~mso-fareast-font-family:"Times New Roman"">10. Ducomble T~~, et al., The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill, 2013; ~~'''~~18~~'''~~(12)~~</span>~~</ref><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman"~~,~~serif;~~
	~~mso-fareast-font-family:"Times New Roman"">11~~. in Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. 2011~~; London~~</~~span~~></ref><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman"~~,~~serif;~~
	~~mso-fareast-font-family:"Times New Roman"">12. Thwaites G~~, et al., British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect, 2009; ~~'''~~59~~'''~~(3): 167-~~87<~~/~~span>~~</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman",serif;~~
	~~mso-fareast-font-family:"Times New Roman"">14.~~ Chin JH, Tuberculous meningitis: Diagnostic and therapeutic challenges. Neurol Clin Pract, 2014; ~~'''~~4~~'''~~(3):199-205</~~span>~~</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span><ref>~~<span style="font-size:12.0pt;font-family:"Times New Roman"~~,~~serif;~~
	~~mso-fareast-font-family:"Times New Roman"">15. Marais S~~, et al., Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis, 2010; ~~'''~~10~~'''~~(11): 803-~~12<~~/~~span>~~</ref><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit;"}" style="box-sizing: inherit;"></span></span>.

	Xpert MTB/Rif, PCR zur Bestimmung von Tbc sowie Rifampicin-Resistenz, welches ein Hinweis für eine MDR-Tbc ist. Die Verlässlichkeit eines resistenten Ergebnisses (positiv prädiktiver Wert) ist abhängig von der Häufigkeit der Resistenz in der untersuchten Bevölkerung. Liegt die MDR-Rate, wie in Deutschland, unter 5%, sinkt der positiv prädiktive Wert auf unter 70% <ref~~><span style~~="~~font-size~~:~~12.0pt;line-height:107%;~~		Xpert MTB/Rif, PCR zur Bestimmung von Tbc sowie Rifampicin-Resistenz, welches ein Hinweis für eine MDR-Tbc ist. Die Verlässlichkeit eines resistenten Ergebnisses (positiv prädiktiver Wert) ist abhängig von der Häufigkeit der Resistenz in der untersuchten Bevölkerung. Liegt die MDR-Rate, wie in Deutschland, unter 5%, sinkt der positiv prädiktive Wert auf unter 70% <ref name=":0" />
	~~font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";~~
	~~mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA~~">8. Schaberg T, et al., Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP). Pneumologie 2017; '''71'''(6): 325-397</span></~~ref~~>

	===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===		===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===

imported>Maximilian.schons@uk-koeln.de: Maximilian.schons@uk-koeln.de verschob die Seite DGI:Tuberkulose Meningitis/Diagnostik nach DGI:ZNS-Infektionen/Tuberkulose Meningitis/Diagnostik: Textersetzung - „Tuberkulose Meningitis“ durch „ZNS-Infektionen/Tuberkulose Meningitis“

2021-08-03T07:39:02Z

Maximilian.schons@uk-koeln.de verschob die Seite DGI:Tuberkulose Meningitis/Diagnostik nach DGI:ZNS-Infektionen/Tuberkulose Meningitis/Diagnostik: Textersetzung - „Tuberkulose Meningitis“ durch „ZNS-Infektionen/Tuberkulose Meningitis“

← Older revision		Revision as of 07:39, 3 August 2021
(No difference)

imported>Fuhrmanns: /* Diagnose */

2021-08-02T15:36:48Z

Diagnose

← Older revision		Revision as of 15:36, 2 August 2021
Line 97:		Line 97:
	*Parasiten: ''Echinokokkus'' spp., Toxoplasma		*Parasiten: ''Echinokokkus'' spp., Toxoplasma
	*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)		*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)
	~~<references />~~

imported>Fuhrmanns: /* Differentialdiagnose */

2021-07-26T08:49:46Z

Differentialdiagnose

← Older revision		Revision as of 08:49, 26 July 2021
Line 94:		Line 94:

	*Andere bakterielle Meningitiden (''Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, Listeria monocytogenes, Streptococcus, agalactiae''), Neuroborreliose		*Andere bakterielle Meningitiden (''Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, Listeria monocytogenes, Streptococcus, agalactiae''), Neuroborreliose
	*Pilze: Candida spp., Aspergillus spp., Kryptokokkus spp.		*Pilze: ''Candida'' spp., ''Aspergillus'' spp., ''Kryptokokkus'' spp.
	*Parasiten: Echinokokkus spp., Toxoplasma		*Parasiten: ''Echinokokkus'' spp., Toxoplasma
	*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)		*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)
	<references />		<references />

imported>Fuhrmanns: /* Differentialdiagnose */

2021-07-26T08:48:05Z

Differentialdiagnose

← Older revision		Revision as of 08:48, 26 July 2021
Line 93:		Line 93:
	===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===		===<span class="mw-headline" id="Differentialdiagnose" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}" style="box-sizing: inherit; font-family: Arial, sans-serif;">Differentialdiagnose</span></span>===

	*Andere bakterielle Meningitiden (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, Listeria monocytogenes, Streptococcus, agalactiae), Neuroborreliose		*Andere bakterielle Meningitiden (''Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, Listeria monocytogenes, Streptococcus, agalactiae''), Neuroborreliose
	*Pilze: Candida spp., Aspergillus spp., Kryptokokkus spp.		*Pilze: Candida spp., Aspergillus spp., Kryptokokkus spp.
	*Parasiten: Echinokokkus spp., Toxoplasma		*Parasiten: Echinokokkus spp., Toxoplasma
	*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)		*Nicht-infektiös: Sarkoidose, tumorös (Meningiosis carcinomatosa)
	<references />		<references />

imported>Fuhrmanns: /* Diagnose */

2021-07-26T08:46:18Z

Diagnose

← Older revision		Revision as of 08:46, 26 July 2021
Line 43:		Line 43:
	\|Normal oder (Pfeil nach oben)		\|Normal oder (Pfeil nach oben)
	\|-		\|-
	!Leukozyten(x 106/l)		!Leukozyten (x 106/l)
	\|1-4		\|1-4
	\|< 1000 Lymphozyten		\|< 1000 Lymphozyten